LY4066434 — Investigational Agent
KRAS Inhibitor · Phase 1 · Eli Lilly
Mechanism of Action
Pan-KRAS small-molecule inhibitor targeting multiple KRAS mutant alleles (beyond G12C, including G12D and other variants), suppressing MAPK-pathway signaling across a broad range of KRAS-driven tumors.
Investigational Indications
- KRAS-mutant NSCLC (non-G12C and G12C)
- KRAS-mutant pancreatic ductal adenocarcinoma
- KRAS-mutant colorectal cancer